Live Yum Brands Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow IMMUCELL CORP /DE/

Get SEC filing alerts via email and in your feed for IMMUCELL CORP /DE/

ICCC

IMMUCELL CORP /DE/

About IMMUCELL CORP /DE/

ImmuCell Corporation specializes in developing and manufacturing animal health products, primarily antibody-based solutions for dairy and beef industries. Its flagship products, First Defense and Re-Tain, focus on preventing calf scours and treating subclinical mastitis. The company leverages proprietary technologies, regulatory approvals, and a global distribution network to deliver innovative, sustainable, and effective solutions that enhance animal health, productivity, and food safety.
This description was generated via AI from an annual report. Updated 10 months ago.

Latest SEC Filings from IMMUCELL CORP /DE/

1
1
IMMUCELL CORP /DE/ ImmuCell Corporation Reports 28.4% Increase in Product Sales for Q1 2026

Via official filing (AI summary) | 2 months ago | 0 comments

2
1
IMMUCELL CORP /DE/ ImmuCell Corporation Reports 4.3% Increase in Product Sales and Improved Gross Margin for Fiscal Year 2025

Via official filing (AI summary) | 4 months ago | 0 comments

3
1
IMMUCELL CORP /DE/ ImmuCell Reports Q3 2025 Financial Results with Improved Gross Margin and Net Operating Income

Via official filing (AI summary) | 8 months ago | 0 comments

4
1
IMMUCELL CORP /DE/ ImmuCell Corporation Reports 17.7% Increase in Product Sales and Net Income Turnaround for Q2 2025

Via official filing (AI summary) | 11 months ago | 0 comments

5
1
IMMUCELL CORP /DE/ ImmuCell Corporation Reports Net Income Turnaround and 11% Sales Growth in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
IMMUCELL CORP /DE/ ImmuCell Corporation Reports 52% Increase in Product Sales for Fiscal Year 2024

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
IMMUCELL CORP /DE/ ImmuCell Corporation Reports 11.4% Revenue Growth, Improved Gross Margins, and Reduced Net Loss in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments